This nutrient is required for fat metabolism and injecting more of this nutrient causes fat loss are different claims, and only the first is supported
Researched applications In the published preclinical and clinical literature the effects of AOD-9604 are documented in the following areas: Obesity , Phase 2b failure (2007), but a complementary mechanism in combination protocols Lipolysis in animal models , robustly demonstrated (Heffernan 2001, Ng 2009) Inhibition of lipogenesis , demonstrated in hepatocytes and adipocytes Osteoarthritis and cartilage regeneration , emerging Phase 1/2 data (mLuna Pharmaceuticals 2018+) Tendinopathy , preclinical models Age-related sarcopenia (cachexia) , exploratory plans Lipodystrophy , preclinical data in animal models Hyperlipidemia , secondary endpoints in Phase 2 trials Science & studies 4.1 Key publications Heffernan M., Summers R.J., Thorburn A., et al
Age plays a role as well, with younger individuals generally recovering more quickly
Comparing Prescription vs
BPC-157 + TB-500 BLEND 2MG/2MG Research Grade The BPC-157 + TB-500 Research Blend co-delivers 2mg of BPC-157 (CAS 137525-51-0) and 2mg of TB-500 (CAS 77591-33-4) in a single co-lyophilised vial